UDR Declares Quarterly Dividends

DENVER--(BUSINESS WIRE)-- UDR, Inc. (NYSE: UDR), a leading multifamily real estate investment trust, today announced that its Board of Directors declared a regular quarterly dividend on its common stock for the first quarter of 2024 in the amount of $0.425 per share, payable in cash on April 30, 2024 to UDR common stock shareholders of record as of April 10, 2024. The April 30, 2024 dividend will be the 206th consecutive quarterly dividend paid by the Company on its common stock.

As previously disclosed in February, the Company’s annualized common dividend of $1.70 per share in 2024 represents a 1.2% increase over the annualized common dividend of $1.68 per share in 2023.

UDR also announced that its Board of Directors declared a regular quarterly dividend on its Series E preferred stock for the first quarter of 2024 in the amount of $0.4602 per share. The preferred dividend is payable on April 30, 2024 to Series E preferred stock shareholders of record as of April 10, 2024.

About UDR, Inc.

UDR, Inc. (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate properties in targeted U.S. markets. As of December 31, 2023, UDR owned or had an ownership position in 60,336 apartment homes including 359 homes under development. For over 51 years, UDR has delivered long-term value to shareholders, the best standard of service to residents and the highest quality experience for associates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240314567620/en/

UDR, Inc.
Trent Trujillo
[email protected]
720-283-6135

Source: UDR, Inc.

You May Also Be Interested In

• Sky9 Capital Expands Into Europe With the Opening of a New Office in Paris
• Ethereum News Today: ETH Shorts Pile Up While Remittix Builds Momentum Ahead of November 24
• Claris Biotherapeutics Releases Positive CSB-001 Clinical Proof-of-Concept Data in Limbal Stem Cell Deficiency at AAO 2026 Annual Meeting